Day: May 13, 2022

Onex Reports First Quarter 2022 Results

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

All amounts in U.S. dollars unless otherwise stated TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2022 and an update on matters following quarter-end. “Onex had a solid start to the year. Our businesses continue to execute, and the fundamentals of our firm are strong. Despite a challenging backdrop, our portfolio is performing well, reflecting the diversification and resiliency of our investments overall,” said Gerry Schwartz, Chairman and Chief Executive Officer of Onex. “We remain focused on delivering on our plan to grow our asset management business and increase long-term value for shareholders.” Financial Results(unaudited)($ millions except per share amounts) Three Months Ended March 31, 2022 Three Months Ended March...

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “2022 has already been an exciting year for Marker as we reported encouraging initial results from the six-patient safety lead-in portion of our Phase 2 AML trial—including elimination of MRD in one MRD positive patient—and announced plans for Company-sponsored...

EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLC Continue to expect first regulatory submissions for aumolertinib and sugemalimab ex-U.S. in 2H 2022; constructive conversations with the FDA are ongoing to gain greater clarity on the regulatory path forward in the U.S. Continue to advance the Global Buyers Club; first conversion of a memorandum of understanding (MOU) to a pre-commercialization agreement EQRx to host conference call and webcast today at 8:00 a.m. ETCAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering...

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Written by Customer Service on May 13, 2022. Posted in Public Companies.

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May and June. Details of the presentations are as follows: American Society of Cell and Gene Therapy (ASGCT) 25th Annual Meeting, May 16-19, Washington and virtualTitle: Autologous Cell & Gene Therapy for the Therapeutic Targeting of Immune Payloads to the Solid Tumor Microenvironment. Preliminary results of the TEM-GBM studyType: Oral presentation during the Clinical Trials Spotlight SymposiumTime: May 19, 2022, 8:45 AM – 9:00 AM ET Brain Tumor Meeting (BTM) 2022, May 19-20, BerlinTitle: Evidence for Interferon alpha mediated disease stabilization...

Vitalhub Corp to Present at the Roth Canada Showcase Day

Written by Customer Service on May 13, 2022. Posted in Public Companies.

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) today announces that will be presenting at the Roth Canada Showcase Day, which will be held in-person at 1 Hotel Central Park, 1414 Avenue of the Americas (58th Street), New York, NY 10019.Event Roth Canada Showcase DayDate May 17th, 2022Presentation 11:00 AM Eastern TimeLocation New York CityThis year’s event will consist of group presentations, 1-on-1 meetings and networking activities by executive management from Canadian-listed companies in a variety of growth sectors, including technology, healthcare and sustainability. To learn more and submit a registration request, visit https://www.roth.com/Canada2022 ABOUT ROTH CAPITAL PARTNERS Roth Capital Partners, LLC (Roth) is a relationship-driven investment bank focused...

Actelis Networks, Inc. Announces Pricing of its Initial Public Offering

Written by Customer Service on May 13, 2022. Posted in Public Companies.

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ:ASNS) (“Actelis” or the “Company”), a provider of cyber-hardened, rapid-deployment networking solutions for wide-area IoT networks, today announced the pricing of its initial public offering of 3,750,000 shares of its common stock (the “Common Stock”) at a public offering price of $4.00 per share, for aggregate gross proceeds of $15.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Boustead Securities, LLC (“Boustead”) is acting as the sole underwriter for the offering. The shares of Common Stock are expected to begin trading on The Nasdaq Capital Market as of today, May 13, 2022, under the symbol “ASNS”. In addition, the Company has granted Boustead, which acted as the sole underwriter for the offering,...

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Written by Customer Service on May 13, 2022. Posted in Public Companies.

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders FORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) — Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc. (“Lay Sciences”), a development and commercialization company of innovative solutions, to license worldwide manufacturing rights to certain Lay Sciences’ IgY products containing avian antibodies as an active ingredient. “The strategic partnership with Lay Sciences has the potential to produce near term revenue,” said Michael K. Handley, President and Chief...

Invesco Ltd.: Form 8.3 – Capital & Counties Properties PLC CORRECTION

Written by Customer Service on May 13, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Capital & Counties Properties plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable...

Ceylon Graphite Closes Upsized $3,500,000 Private Placement and Extension of Debentures

Written by Customer Service on May 13, 2022. Posted in Public Companies.

VANCOUVER, May 13, 2022 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon” or the “Company”) (TSXV: CYL) (OTCQB: CYLYF) (FSE: CCY) is pleased to announce that further to its press releases of April 6 and 7, 2022, it has closed a private placement of 21,875,000 units (“Units”) at a price of $0.16 per Unit for gross proceeds of $3,500,000 (the “Offering”). Each Unit consists of one common share in the capital of the Company (“Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder thereof to acquire one common share of the Company (each a “Warrant Share”) at a price of $0.25 per Warrant Share at any time until May 10, 2025. Ceylon intends to use the net proceeds of the Offering to advance the Company’s K1 and M1 mines to commercial production. The Company anticipates achieving this milestone within...

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. “We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging,” stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. “HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing a condition.” Dr. Wong continued, “Our...

Day: May 13, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals